254 related articles for article (PubMed ID: 15983551)
21. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
22. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Phillips GL; Bernstein SH; Liesveld JL; Abboud CN; Becker MW; Constine LS; Ifthikharuddin JJ; Loughner JE; Milner LA; Vesole DH; Friedberg JW
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1033-42. PubMed ID: 21074630
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
24. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.
Cerchietti LC; Navigante AH; Bonomi MR; Zaderajko MA; Menéndez PR; Pogany CE; Roth BM
Cancer; 2002 Nov; 95(10):2230-6. PubMed ID: 12412178
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT: a double-blind, randomized, placebo-controlled trial.
Hosseinjani H; Hadjibabaie M; Gholami K; Javadi M; Radfar M; Jahangard-Rafsanjani Z; Hosseinjani E; Shabani N; Vaezi M; Ghavamzadeh A
Hematol Oncol; 2017 Mar; 35(1):106-112. PubMed ID: 26310513
[TBL] [Abstract][Full Text] [Related]
26. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial.
Karthaus M; Rosenthal C; Huebner G; Paul H; Elser C; Hertenstein B; Krauter J; Scharmann T; Geissler RG; Heil G; Ganser A
Bone Marrow Transplant; 1998 Oct; 22(8):781-5. PubMed ID: 9827976
[TBL] [Abstract][Full Text] [Related]
27. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study.
Valcárcel D; Sanz MA; Sureda A; Sala M; Muñoz L; Subirá M; Laborda R; Clopés A; Sierra J
Bone Marrow Transplant; 2002 May; 29(9):783-7. PubMed ID: 12040477
[TBL] [Abstract][Full Text] [Related]
28. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
29. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L
Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675
[TBL] [Abstract][Full Text] [Related]
30. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
[TBL] [Abstract][Full Text] [Related]
31. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
[TBL] [Abstract][Full Text] [Related]
32. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Phillips GL; Abboud CN; Bernstein SH; Friedberg JW; Ifthikharuddin JJ; Lancet JE; Liesveld JL; Spreng E; Johnson V; Chapman M; Vesole DH
Semin Oncol; 2004 Dec; 31(6 Suppl 18):59-61. PubMed ID: 15726525
[TBL] [Abstract][Full Text] [Related]
33. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study.
Vokurka S; Bystrická E; Koza V; Scudlová J; Pavlicová V; Valentová D; Bocková J; Misaniová L
Support Care Cancer; 2005 Jul; 13(7):554-8. PubMed ID: 15798915
[TBL] [Abstract][Full Text] [Related]
34. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2).
Glossmann JP; Josting A; Pfistner B; Paulus U; Engert A;
Ann Hematol; 2002 Aug; 81(8):424-9. PubMed ID: 12223998
[No Abstract] [Full Text] [Related]
36. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
[TBL] [Abstract][Full Text] [Related]
37. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
38. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Spencer A; Horvath N; Gibson J; Prince HM; Herrmann R; Bashford J; Joske D; Grigg A; McKendrick J; Prosser I; Lowenthal R; Deveridge S; Taylor K;
Bone Marrow Transplant; 2005 May; 35(10):971-7. PubMed ID: 15778725
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
40. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
